|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:activeIngredient
|
nucleoside-modified mRNA encoding SARS-CoV-2 spike protein
|
|
gptkbp:adverseEventReportingSystem
|
gptkb:EudraVigilance_(EU)
gptkb:VAERS_(US)
gptkb:Yellow_Card_(UK)
|
|
gptkbp:age
|
12 years and older
5-11 years (lower dose)
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:boosterDoseAvailable
|
yes
|
|
gptkbp:boosterInterval
|
at least 5 months after second dose
|
|
gptkbp:boosterRecommended
|
yes
|
|
gptkbp:brand
|
gptkb:Comirnaty
|
|
gptkbp:clinicalTrialPhase
|
July 2020 - November 2020
|
|
gptkbp:contains
|
gptkb:plastic
sodium chloride
potassium chloride
saline
sucrose
lipid nanoparticles
water for injection
dibasic sodium phosphate dihydrate
monobasic potassium phosphate
|
|
gptkbp:containsAdjuvant
|
no
|
|
gptkbp:containsAluminum
|
no
|
|
gptkbp:containsEggProducts
|
no
|
|
gptkbp:containsGelatin
|
no
|
|
gptkbp:containsHumanOrAnimalProducts
|
no
|
|
gptkbp:containsLatex
|
no
|
|
gptkbp:containsMercury
|
no
|
|
gptkbp:containsPreservatives
|
no
|
|
gptkbp:containsThimerosal
|
no
|
|
gptkbp:developedBy
|
gptkb:Pfizer
gptkb:BioNTech
|
|
gptkbp:dilutionRequired
|
yes
|
|
gptkbp:distributor
|
gptkb:Fosun_Pharma_(China)
BioNTech (Europe)
Pfizer (US and other countries)
|
|
gptkbp:dosageSchedule
|
two doses, 3 weeks apart
|
|
gptkbp:efficacyAgainstOriginalStrain
|
~95%
|
|
gptkbp:EMARecommended
|
yes
|
|
gptkbp:emergencyServices
|
December 2020
|
|
gptkbp:emergencyUseInChildren
|
yes
|
|
gptkbp:emergencyUseInPregnancy
|
yes
|
|
gptkbp:firstAuthorizationDate
|
2 December 2020
|
|
gptkbp:firstCountryToAuthorize
|
gptkb:United_Kingdom
|
|
gptkbp:firstDosesAdministered
|
December 2020
|
|
gptkbp:fullApprovalDate
|
August 2021
|
|
gptkbp:globalDosesAdministered
|
over 1 billion (2022)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pfizer–BioNTech COVID-19 vaccine
|
|
gptkbp:includedInCOVAX
|
yes
|
|
gptkbp:marketedIn
|
over 100 countries
|
|
gptkbp:needleGaugeRecommended
|
23–25 gauge
|
|
gptkbp:needleLengthRecommended
|
1–1.5 inches
|
|
gptkbp:NHSRecommended
|
yes
|
|
gptkbp:patent
|
gptkb:Pfizer
gptkb:BioNTech
|
|
gptkbp:platform
|
gptkb:gene
|
|
gptkbp:pregnancyCategory
|
generally considered safe
consult healthcare provider
|
|
gptkbp:rareSideEffects
|
pericarditis
anaphylaxis
myocarditis
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:shelfLifeFrozen
|
6 months
|
|
gptkbp:shelfLifeRefrigerated
|
1 month
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
muscle pain
chills
pain at injection site
|
|
gptkbp:storage
|
-70°C
|
|
gptkbp:storageAfterThawing
|
2–8°C for up to 1 month
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:trialParticipantsPhase3
|
over 43,000
|
|
gptkbp:USCDCRecommended
|
yes
|
|
gptkbp:variantAdaptedFormulations
|
Omicron-adapted
|
|
gptkbp:vialDoseCount
|
6 doses per vial
|
|
gptkbp:WHOEmergencyUseListing
|
December 2020
|
|
gptkbp:bfsParent
|
gptkb:Margaret_Keenan
gptkb:COVID-19_vaccines
gptkb:COVID-19_vaccine_development_(Moderna)
gptkb:COVID-19_vaccination_campaign
gptkb:辉瑞新冠疫苗
|
|
gptkbp:bfsLayer
|
6
|